Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.83 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.83 |
| ▸ | MTOR | P42345 | 8/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737885 | 0.94 | PIK3CA (0.74) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL739763 | 0.93 | PIK3CA (0.71) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL738520 | 0.91 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL738315 | 0.91 | PIK3CA (0.68) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL739807 | 0.88 | PIK3CA (0.83) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL737932 | 0.87 | PIK3CA (0.81) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL3597508 | 0.85 | PIK3CA (0.76) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL737528 | 0.84 | PIK3CA (0.58) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL3930038 | 0.84 | PIK3CA (0.81) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL738603 | 0.83 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | claimed |
| EP-4192822-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | HOFFMANN-LA ROCHE, INC. (US) | 2022-05-24 | — | — | US | claimed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | claimed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | claimed |
| WO-2021052892-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-25 | — | — | WO | claimed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | claimed |
| US-20190298726-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | claimed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | claimed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | claimed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| EP-2176238-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2012-04-18 | — | — | EP | claimed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | claimed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | claimed |
| EP-2176238-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009007750-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | claimed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | PIK3CA 2825/4885PIK3CD 3931/4885MTOR 590/4885 |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | PIK3CA 2825/4885PIK3CD 3931/4885MTOR 590/4885 |
| US-20190298726-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | TLR7, TLR9, HAVCR2 | PIK3CA 2458/4885PIK3CD 2647/4885MTOR 3990/4885 |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | PNPO, PDXK, C5 | PIK3CA 1305/4885PIK3CD 1675/4885MTOR 2092/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | PIK3CA 2249/4885PIK3CD 3811/4885MTOR 1370/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | PIK3CA 20/4885PIK3CD 19/4885MTOR 3/4885 |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | TLR7, TLR9, HAVCR2 | PIK3CA 2458/4885PIK3CD 2647/4885MTOR 3990/4885 |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | PIK3CA, MTOR, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885MTOR 2/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | PIK3CA 1658/4885PIK3CD 3571/4885MTOR 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.